{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30","upperLimit":"78","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause. PFS will be based on the investigator's assessment of MRI, CSF studies and clinical presentation.","dispersionType":"Full Range","groups":[{"description":"This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).","id":"OG000","title":"Buparlisib (BKM120)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"days"}